Clinical trial
ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
NCT00046514 · Celgene Corporation, Industry · Completed
Key facts
| NCT number | NCT00046514 |
|---|---|
| Title | ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer |
| Official title | A Phase II Clinical Trial of ABI-007 (A Cremophor-Free, Protein Stabilized, Nanoparticle Paclitaxel)Administered Weekly in Taxol Resistant Patients With Metastatic Breast Cancer |
| Lead sponsor | Celgene Corporation, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Metastases, Neoplasm |
| Intervention type | Drug |
| Interventions | ABI-007 |
| Enrollment | 100 |
| Start date | Jun 1, 2001 |
| First posted | Oct 3, 2002 |
| Last update posted | Dec 15, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: